Literature DB >> 27193704

Advanced lymphoblastic clones detection in T-cell leukemia.

A A Minervina1, A Y Komkov1, I Z Mamedov1, Y B Lebedev2.   

Abstract

T cell acute lymphoblastic leukemia (T-ALL) is an aggressive malignant neoplasm of the lymphocyte precursors that suffered malignant transformation arresting the lymphoid cell differentiation. Clinical studies revealed monoor, more rarely, oligoclonal nature of the disease. A precise identification of malignant clone markers is both the crucial stage of early diagnostics and the essential prognostic factor for therapeutic treatment. Here we present an improved system for unbiased detection of lymphoblastic clones in bone marrow aspirates of T-ALL patients. The system based on multiplex PCR of rearranged T-cell receptor locus (TRB) and straightforward sequencing of the resulted PCR fragments. Testing of the system on genomic DNA from Jurkat cell line and four clinical bone marrow aspirates revealed a set of unique TRB rearrangements that precisely characterize each of tested samples. Therefore, the outcome of the system produces highly informative molecular genetic markers for further monitoring of minimal residual disease in T-ALL patients.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27193704     DOI: 10.1134/S1607672916020022

Source DB:  PubMed          Journal:  Dokl Biochem Biophys        ISSN: 1607-6729            Impact factor:   0.788


  13 in total

Review 1.  Minimal residual disease monitoring in childhood acute lymphoblastic leukemia.

Authors:  Dario Campana
Journal:  Curr Opin Hematol       Date:  2012-07       Impact factor: 3.284

2.  First autologous hematopoietic SCT for ankylosing spondylitis: a case report and clues to understanding the therapy.

Authors:  O V Britanova; A G Bochkova; D B Staroverov; D A Fedorenko; D A Bolotin; I Z Mamedov; M A Turchaninova; E V Putintseva; A A Kotlobay; S Lukyanov; A A Novik; Y B Lebedev; D M Chudakov
Journal:  Bone Marrow Transplant       Date:  2012-03-12       Impact factor: 5.483

3.  Human T-cell lines with well-defined T-cell receptor gene rearrangements as controls for the BIOMED-2 multiplex polymerase chain reaction tubes.

Authors:  Y Sandberg; B Verhaaf; E J van Gastel-Mol; I L M Wolvers-Tettero; J de Vos; R A F Macleod; J G Noordzij; W A Dik; J J M van Dongen; A W Langerak
Journal:  Leukemia       Date:  2006-12-14       Impact factor: 11.528

4.  The clinical path to integrated genomics in ALL.

Authors:  Jean-Pierre Bourquin
Journal:  Blood       Date:  2014-08-28       Impact factor: 22.113

Review 5.  Acute lymphoblastic leukaemia.

Authors:  Hiroto Inaba; Mel Greaves; Charles G Mullighan
Journal:  Lancet       Date:  2013-03-22       Impact factor: 79.321

6.  Deep-sequencing approach for minimal residual disease detection in acute lymphoblastic leukemia.

Authors:  Malek Faham; Jianbiao Zheng; Martin Moorhead; Victoria E H Carlton; Patricia Stow; Elaine Coustan-Smith; Ching-Hon Pui; Dario Campana
Journal:  Blood       Date:  2012-10-16       Impact factor: 22.113

Review 7.  Biological markers in haematological malignancies.

Authors:  Richard Lemal; Olivier Tournilhac; Jacques-Olivier Bay
Journal:  Bull Cancer       Date:  2014-06       Impact factor: 1.276

8.  Minimal residual disease quantification using consensus primers and high-throughput IGH sequencing predicts post-transplant relapse in chronic lymphocytic leukemia.

Authors:  A C Logan; B Zhang; B Narasimhan; V Carlton; J Zheng; M Moorhead; M R Krampf; C D Jones; A N Waqar; M Faham; J L Zehnder; D B Miklos
Journal:  Leukemia       Date:  2013-02-19       Impact factor: 11.528

9.  Preparing unbiased T-cell receptor and antibody cDNA libraries for the deep next generation sequencing profiling.

Authors:  Ilgar Z Mamedov; Olga V Britanova; Ivan V Zvyagin; Maria A Turchaninova; Dmitriy A Bolotin; Ekaterina V Putintseva; Yuriy B Lebedev; Dmitriy M Chudakov
Journal:  Front Immunol       Date:  2013-12-23       Impact factor: 7.561

Review 10.  EuroFlow standardization of flow cytometer instrument settings and immunophenotyping protocols.

Authors:  T Kalina; J Flores-Montero; V H J van der Velden; M Martin-Ayuso; S Böttcher; M Ritgen; J Almeida; L Lhermitte; V Asnafi; A Mendonça; R de Tute; M Cullen; L Sedek; M B Vidriales; J J Pérez; J G te Marvelde; E Mejstrikova; O Hrusak; T Szczepański; J J M van Dongen; A Orfao
Journal:  Leukemia       Date:  2012-09       Impact factor: 11.528

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.